AstraZeneca (AZN -3%) would consider $3-4B acquisitions and product deals of $500-$600M,...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

AstraZeneca (AZN -3%) would consider $3-4B acquisitions and product deals of $500-$600M, although a large "disruptive" purchase is unlikely, says CEO Pascal Soriot following Q4 earnings. AZN, which is keeping buybacks on hold, won't raise its dividend for the first time in a decade. The firm is in the midst of a patent cliff, having lost exclusivity to Seroquel (schizophrenia) last year, and it's set to lose protection for Nexium (ulcers) and Crestor (cholestoral) in 2014 and 2016 respectively.